Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

Nicolas Wentzensen, Megan A. Clarke, Renee Bremer, Nancy Poitras, Diane Tokugawa, Patricia E. Goldhoff, Philip E. Castle, Mark Schiffman, Julie D. Kingery, Kiranjit K. Grewal, Alex Locke, Walter Kinney, Thomas S. Lorey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Importance: As cervical cancer screening transitions from Papanicolaou cytologic screening to primary human papillomavirus (HPV) testing worldwide, effective triage tests are needed to decide who among the HPV-positive women should receive further diagnostic evaluation to avoid unnecessary colposcopies and biopsies. Objective: To evaluate the performance of the p16/Ki-67 dual stain (DS) and HPV16/18 genotyping for the triage of HPV-positive women. Design, Setting, and Participants: A prospective observational study was conducted within the cervical cancer screening program at Kaiser Permanente Northern California of 3225 HPV-positive women undergoing HPV and Papanicolaou cytologic testing with a valid DS result from September 16 to October 31, 2015, with follow-up through December 31, 2018. Exposures: Human papillomavirus screening with partial genotyping and cytologic triage compared with DS triage. Main Outcomes and Measures: Cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) and grade 2 or more severe (CIN2+), diagnosed within 3 years after sample collection. Results: A total of 3225 women (mean [SD] age, 37.9 [11.3] years) participated in the study. For triage of HPV-positive women with partial genotyping, DS showed better risk stratification for CIN3+ than did Papanicolaou cytologic testing, with women with positive DS results having a higher risk than women with positive Papanicolaou test results for CIN3+ (218 of 1818 [12.0%; 95% CI, 10.5%-13.5%] vs 219 of 2128 [10.3%; 95% CI, 9.0%-11.6%]; P =.005). Similarly, DS showed better risk stratification for CIN3+ compared with Papanicolaou cytologic testing in HPV-positive women, irrespective of genotyping. The greatest reassurance against CIN3+ was observed in HPV16/18-negative women with negative DS results, with a risk low enough to extend retesting intervals. Dual stain triage strategies required substantially fewer colposcopies per detection of CIN3+ compared with Papanicolaou cytologic testing, with a 32.1% (859 of 2677) reduction of colposcopies compared with the currently recommended triage strategy of HPV screening with Papanicolaou cytologic testing. Results for CIN2+ were very similar. Conclusions and Relevance: Triage of HPV-positive women with DS was superior to Papanicolaou cytologic testing in this study, demonstrating equal immediate detection of precancerous lesions and substantially reduced referral to colposcopy. These findings suggest that DS can safely replace Papanicolaou cytologic testing as a triage strategy for primary HPV screening, and that retesting intervals in HPV16/18-negative women with negative DS results can be safely extended to 3 years.

Original languageEnglish (US)
JournalJAMA Internal Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Triage
Early Detection of Cancer
Uterine Cervical Neoplasms
Coloring Agents
Colposcopy
Papanicolaou Test
Cervical Intraepithelial Neoplasia
Observational Studies
Referral and Consultation
Outcome Assessment (Health Care)
Prospective Studies
Biopsy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. / Wentzensen, Nicolas; Clarke, Megan A.; Bremer, Renee; Poitras, Nancy; Tokugawa, Diane; Goldhoff, Patricia E.; Castle, Philip E.; Schiffman, Mark; Kingery, Julie D.; Grewal, Kiranjit K.; Locke, Alex; Kinney, Walter; Lorey, Thomas S.

In: JAMA Internal Medicine, 01.01.2019.

Research output: Contribution to journalArticle

Wentzensen, N, Clarke, MA, Bremer, R, Poitras, N, Tokugawa, D, Goldhoff, PE, Castle, PE, Schiffman, M, Kingery, JD, Grewal, KK, Locke, A, Kinney, W & Lorey, TS 2019, 'Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program', JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.0306
Wentzensen, Nicolas ; Clarke, Megan A. ; Bremer, Renee ; Poitras, Nancy ; Tokugawa, Diane ; Goldhoff, Patricia E. ; Castle, Philip E. ; Schiffman, Mark ; Kingery, Julie D. ; Grewal, Kiranjit K. ; Locke, Alex ; Kinney, Walter ; Lorey, Thomas S. / Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. In: JAMA Internal Medicine. 2019.
@article{e18fed5dbbcd42e7b7e1a61c1bb9bfd1,
title = "Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program",
abstract = "Importance: As cervical cancer screening transitions from Papanicolaou cytologic screening to primary human papillomavirus (HPV) testing worldwide, effective triage tests are needed to decide who among the HPV-positive women should receive further diagnostic evaluation to avoid unnecessary colposcopies and biopsies. Objective: To evaluate the performance of the p16/Ki-67 dual stain (DS) and HPV16/18 genotyping for the triage of HPV-positive women. Design, Setting, and Participants: A prospective observational study was conducted within the cervical cancer screening program at Kaiser Permanente Northern California of 3225 HPV-positive women undergoing HPV and Papanicolaou cytologic testing with a valid DS result from September 16 to October 31, 2015, with follow-up through December 31, 2018. Exposures: Human papillomavirus screening with partial genotyping and cytologic triage compared with DS triage. Main Outcomes and Measures: Cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) and grade 2 or more severe (CIN2+), diagnosed within 3 years after sample collection. Results: A total of 3225 women (mean [SD] age, 37.9 [11.3] years) participated in the study. For triage of HPV-positive women with partial genotyping, DS showed better risk stratification for CIN3+ than did Papanicolaou cytologic testing, with women with positive DS results having a higher risk than women with positive Papanicolaou test results for CIN3+ (218 of 1818 [12.0{\%}; 95{\%} CI, 10.5{\%}-13.5{\%}] vs 219 of 2128 [10.3{\%}; 95{\%} CI, 9.0{\%}-11.6{\%}]; P =.005). Similarly, DS showed better risk stratification for CIN3+ compared with Papanicolaou cytologic testing in HPV-positive women, irrespective of genotyping. The greatest reassurance against CIN3+ was observed in HPV16/18-negative women with negative DS results, with a risk low enough to extend retesting intervals. Dual stain triage strategies required substantially fewer colposcopies per detection of CIN3+ compared with Papanicolaou cytologic testing, with a 32.1{\%} (859 of 2677) reduction of colposcopies compared with the currently recommended triage strategy of HPV screening with Papanicolaou cytologic testing. Results for CIN2+ were very similar. Conclusions and Relevance: Triage of HPV-positive women with DS was superior to Papanicolaou cytologic testing in this study, demonstrating equal immediate detection of precancerous lesions and substantially reduced referral to colposcopy. These findings suggest that DS can safely replace Papanicolaou cytologic testing as a triage strategy for primary HPV screening, and that retesting intervals in HPV16/18-negative women with negative DS results can be safely extended to 3 years.",
author = "Nicolas Wentzensen and Clarke, {Megan A.} and Renee Bremer and Nancy Poitras and Diane Tokugawa and Goldhoff, {Patricia E.} and Castle, {Philip E.} and Mark Schiffman and Kingery, {Julie D.} and Grewal, {Kiranjit K.} and Alex Locke and Walter Kinney and Lorey, {Thomas S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamainternmed.2019.0306",
language = "English (US)",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Clinical Evaluation of Human Papillomavirus Screening with p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

AU - Wentzensen, Nicolas

AU - Clarke, Megan A.

AU - Bremer, Renee

AU - Poitras, Nancy

AU - Tokugawa, Diane

AU - Goldhoff, Patricia E.

AU - Castle, Philip E.

AU - Schiffman, Mark

AU - Kingery, Julie D.

AU - Grewal, Kiranjit K.

AU - Locke, Alex

AU - Kinney, Walter

AU - Lorey, Thomas S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: As cervical cancer screening transitions from Papanicolaou cytologic screening to primary human papillomavirus (HPV) testing worldwide, effective triage tests are needed to decide who among the HPV-positive women should receive further diagnostic evaluation to avoid unnecessary colposcopies and biopsies. Objective: To evaluate the performance of the p16/Ki-67 dual stain (DS) and HPV16/18 genotyping for the triage of HPV-positive women. Design, Setting, and Participants: A prospective observational study was conducted within the cervical cancer screening program at Kaiser Permanente Northern California of 3225 HPV-positive women undergoing HPV and Papanicolaou cytologic testing with a valid DS result from September 16 to October 31, 2015, with follow-up through December 31, 2018. Exposures: Human papillomavirus screening with partial genotyping and cytologic triage compared with DS triage. Main Outcomes and Measures: Cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) and grade 2 or more severe (CIN2+), diagnosed within 3 years after sample collection. Results: A total of 3225 women (mean [SD] age, 37.9 [11.3] years) participated in the study. For triage of HPV-positive women with partial genotyping, DS showed better risk stratification for CIN3+ than did Papanicolaou cytologic testing, with women with positive DS results having a higher risk than women with positive Papanicolaou test results for CIN3+ (218 of 1818 [12.0%; 95% CI, 10.5%-13.5%] vs 219 of 2128 [10.3%; 95% CI, 9.0%-11.6%]; P =.005). Similarly, DS showed better risk stratification for CIN3+ compared with Papanicolaou cytologic testing in HPV-positive women, irrespective of genotyping. The greatest reassurance against CIN3+ was observed in HPV16/18-negative women with negative DS results, with a risk low enough to extend retesting intervals. Dual stain triage strategies required substantially fewer colposcopies per detection of CIN3+ compared with Papanicolaou cytologic testing, with a 32.1% (859 of 2677) reduction of colposcopies compared with the currently recommended triage strategy of HPV screening with Papanicolaou cytologic testing. Results for CIN2+ were very similar. Conclusions and Relevance: Triage of HPV-positive women with DS was superior to Papanicolaou cytologic testing in this study, demonstrating equal immediate detection of precancerous lesions and substantially reduced referral to colposcopy. These findings suggest that DS can safely replace Papanicolaou cytologic testing as a triage strategy for primary HPV screening, and that retesting intervals in HPV16/18-negative women with negative DS results can be safely extended to 3 years.

AB - Importance: As cervical cancer screening transitions from Papanicolaou cytologic screening to primary human papillomavirus (HPV) testing worldwide, effective triage tests are needed to decide who among the HPV-positive women should receive further diagnostic evaluation to avoid unnecessary colposcopies and biopsies. Objective: To evaluate the performance of the p16/Ki-67 dual stain (DS) and HPV16/18 genotyping for the triage of HPV-positive women. Design, Setting, and Participants: A prospective observational study was conducted within the cervical cancer screening program at Kaiser Permanente Northern California of 3225 HPV-positive women undergoing HPV and Papanicolaou cytologic testing with a valid DS result from September 16 to October 31, 2015, with follow-up through December 31, 2018. Exposures: Human papillomavirus screening with partial genotyping and cytologic triage compared with DS triage. Main Outcomes and Measures: Cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) and grade 2 or more severe (CIN2+), diagnosed within 3 years after sample collection. Results: A total of 3225 women (mean [SD] age, 37.9 [11.3] years) participated in the study. For triage of HPV-positive women with partial genotyping, DS showed better risk stratification for CIN3+ than did Papanicolaou cytologic testing, with women with positive DS results having a higher risk than women with positive Papanicolaou test results for CIN3+ (218 of 1818 [12.0%; 95% CI, 10.5%-13.5%] vs 219 of 2128 [10.3%; 95% CI, 9.0%-11.6%]; P =.005). Similarly, DS showed better risk stratification for CIN3+ compared with Papanicolaou cytologic testing in HPV-positive women, irrespective of genotyping. The greatest reassurance against CIN3+ was observed in HPV16/18-negative women with negative DS results, with a risk low enough to extend retesting intervals. Dual stain triage strategies required substantially fewer colposcopies per detection of CIN3+ compared with Papanicolaou cytologic testing, with a 32.1% (859 of 2677) reduction of colposcopies compared with the currently recommended triage strategy of HPV screening with Papanicolaou cytologic testing. Results for CIN2+ were very similar. Conclusions and Relevance: Triage of HPV-positive women with DS was superior to Papanicolaou cytologic testing in this study, demonstrating equal immediate detection of precancerous lesions and substantially reduced referral to colposcopy. These findings suggest that DS can safely replace Papanicolaou cytologic testing as a triage strategy for primary HPV screening, and that retesting intervals in HPV16/18-negative women with negative DS results can be safely extended to 3 years.

UR - http://www.scopus.com/inward/record.url?scp=85065572819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065572819&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2019.0306

DO - 10.1001/jamainternmed.2019.0306

M3 - Article

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

ER -